Azimilide dihydrochloride
Author:
- 1 May 2005
- journal article
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 3 (3) , 387-391
Abstract
Azimilide dihydrochloride is an antiarrhythmic drug with Vaughn Williams class III properties, which blocks both fast (IKr) and slow (IKs) components of the delayed rectifier cardiac potassium channel. The drug slows the heart rate slightly and, like other class III antiarrhythmic drugs, prolongs ventricular repolarization and thus, the QT interval. Unlike sotalol, another class III antiarrhythmic drug, azimilide does not exhibit reverse-use dependence, that is, its binding characteristics and effectiveness are not related to the heart rate. Azimilide is 85% bioavailable, reaches peak blood concentrations in 6-8 h and has a long elimination half-life of 114 h. Clinical trials have utilized once-daily dosing. These trials have tested the use of the drug for patients with supraventricular and ventricular arrhythmias.Keywords
This publication has 9 references indexed in Scilit:
- Placebo-Controlled, Randomized Clinical Trial of Azimilide for Prevention of Ventricular Tachyarrhythmias in Patients With an Implantable Cardioverter DefibrillatorCirculation, 2004
- The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunctionJACC, 2004
- Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillatorsJACC, 2004
- Azimilide for Atrial Fibrillation: Clinical Trial Results and ImplicationsCardiac Electrophysiology Review, 2003
- Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: Efficacy and dose-responseAmerican Heart Journal, 2002
- Effects of Azimilide on Heart Rate and ECG Conduction Intervals during Sinus Rhythm in Patients with a History of Atrial FibrillationThe Journal of Clinical Pharmacology, 2002
- Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillationThe American Journal of Cardiology, 2001
- Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-responseJACC, 2000
- Pharmacology of Azimilide Dihydrochloride (NE‐10064), A Class III Antiarrhythmic AgentCardiovascular Drug Reviews, 1997